Efprezimod alfa + Methotrexate + Tacrolimus + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia

Trial Timeline

Sep 19, 2016 → May 18, 2021

NCT ID

NCT02663622

About Efprezimod alfa + Methotrexate + Tacrolimus + Placebo

Efprezimod alfa + Methotrexate + Tacrolimus + Placebo is a phase 2 stage product being developed by Merck for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02663622. Target conditions include Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in Graft Versus Host Disease were approved

Approved (20) Terminated (1) Active (0)

✅Prograf + Methotrexate + CyclosporineAstellas PharmaApproved

✅tacrolimusAstellas PharmaApproved

✅azathioprine + sirolimusAstellas PharmaApproved

✅Aspirin + TicagrelorAstraZenecaApproved

✅SugammadexMerckApproved

✅RuxolitinibNovartisApproved

✅CyclosporineNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02663622	Phase 2	Completed	Sep 19, 2016	May 18, 2021	Graft Versus Host Disease

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors

Product	Company	Stage	Hype Score
Prograf + Methotrexate + Cyclosporine	Astellas Pharma	Approved	43
Alefacept	Astellas Pharma	Phase 2	27
tacrolimus	Astellas Pharma	Approved	43
Tacrolimus + Tacrolimus	Astellas Pharma	Pre-clinical	26
azathioprine + sirolimus	Astellas Pharma	Approved	43
Itolizumab + EQ001 Placebo	Biocon	Phase 3	32
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	32
SHR0302	Jiangsu Hengrui Medicine	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	39
Aspirin + Ticagrelor	AstraZeneca	Approved	43
Sugammadex	Merck	Approved	43
Ruxolitinib	Novartis	Approved	50
Imatinib Mesylate and Nilotinib	Novartis	Phase 2	35
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	42
PredEver	Novartis	Phase 2	35
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	29
Cyclosporine	Novartis	Approved	39
Everolimus + Tacrolimus + Mycophenolic acid	Novartis	Approved	39
1 + 2	Novartis	Approved	43
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin	Novartis	Approved	43